ESR1 and breast carcinoma: The TB compound was evaluated against Estrogen Receptor-Positive Human Breast Cancer (MCF-7), Triple-Negative Human Breast Cancer (MDA-MB-231), and HER2-Positive Human Breast Cancer (SK-BR-3) cell lines by CCK-8 assays and was found to have significant anticancer activity in the MCF-7 cell line.